Disease · MONDO_0007243
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Overall Response (Complete Response + Partial Response) | 216 of 235 | 94 of 112 | 347 | NCT00001337 | Trial comparisons |
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 235 of 235 | 112 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Progression Free Survival (PFS) | 73 of 235 | 41 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): deaths from any cause | 28 of 235 | 13 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): serious adverse events | 146 of 235 | 44 of 112 | 347 | NCT00001337 | Trial comparisons |
| Tisagenlecleucel - Post-infusion vs Tisagenlecleucel - Pre-infusion Deaths: deaths from any cause | 17 of 33 | 1 of 34 | 67 | NCT03610724 | Trial comparisons |
| Conventional Care vs Intensive Insulin: serious adverse events | 9 of 25 | 10 of 26 | 51 | NCT00500240 | Trial comparisons |
| Part 2: Ibrutinib+CIT (RICE or RVICI) vs Part 2: Chemoimmunotherapy: Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation | 13 of 35 | 7 of 16 | 51 | NCT02703272 | Trial comparisons |
| Regimen A (R-CODOX-M Chemotherapy) vs Regimen B (Rituximab and IVAC Chemotherapy): serious adverse events | 0 of 2 | 23 of 32 | 34 | NCT00392834 | Trial comparisons |
| Part 1: Ibrutinib vs Part 2: Ibrutinib: Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy | 5 of 15 | 5 of 13 | 28 | NCT02703272 | Trial comparisons |
| Part 2: Ibrutinib+CIT (RICE or RVICI) vs Part 2: Chemoimmunotherapy: Part 2: Number of Participants With c-MYC Gene Rearrangement | 1 of 18 | 1 of 9 | 27 | NCT02703272 | Trial comparisons |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles vs Low Risk - Treatment With 3 Cycles of R-CODOX-M: deaths from any cause | 4 of 20 | 0 of 5 | 25 | NCT00392990 | Trial comparisons |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles vs Low Risk - Treatment With 3 Cycles of R-CODOX-M: serious adverse events | 20 of 20 | 2 of 5 | 25 | NCT00392990 | Trial comparisons |
| Low Risk vs High Risk: Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | 2 of 2 | 7 of 8 | 10 | NCT00126191 | Trial comparisons |
| Low Risk vs High Risk: serious adverse events | 1 of 2 | 2 of 8 | 10 | NCT00126191 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: Number of Participants With Dose Limiting-toxicity (DLT) | 2 of 5 | 1 of 3 | 8 | NCT04933617 | Trial comparisons |
Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 5 of 5 | 3 of 3 | 8 | NCT04933617 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: deaths from any cause | 5 of 5 | 0 of 3 | 8 | NCT04933617 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: serious adverse events | 2 of 5 | 0 of 3 | 8 | NCT04933617 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007243/comparisons